Lartruvo FDA Approval History
Last updated by Judith Stewart, BPharm on May 4, 2021.
FDA Approved: Yes (Discontinued) (First approved October 19, 2016)
Brand name: Lartruvo
Generic name: olaratumab
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Soft Tissue Sarcoma
Lartruvo (olaratumab) is a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody indicated in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma (STS).
Development timeline for Lartruvo
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.